Skip to main content
OpenTrials
Completed

NCT Number: NCT02581553

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Austin, Texas, 78744, United States

About this study

The study comprises 2 parts. Part 1 will assess the relative BA of lesinurad/allopurinol FDC and monocomponents in fasted subjects. Part 2 will assess the effect of food on the PK of FDC tablets.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index ranging between 18 kg/m2 and 40 kg/m2.
  • Screening serum urate level is ≤ 7.0 mg/dL.

Exclusion criteria

  • Asian subject who has a positive test for the HLA-B*5801 allele.
  • History or suspicion of kidney stones.
  • Estimated creatinine clearance, as determined at Screening, of < 90 mL/min calculated by the Cockcroft-Gault formula using ideal body weight.
  • Undergone major surgery within 3 months prior to Screening.
  • Donated blood or experienced significant blood loss (> 450 mL) within 12 weeks prior to Day 1or has given a plasma donation within 4 weeks prior to Day 1.
  • Inadequate venous access or unsuitable veins for repeated venipuncture.
  • Received any strong or moderate enzyme-inducing drug or product within 2 months prior to Screening.

Treatment and study plan

lesinurad/allopurinol 200/300 FDC tablets

Drug

lesinurad 200 mg

Drug

Allopurinol 300 MG

Drug

lesinurad/allopurinol 200/200 FDC tablets

Drug

allopurinol 200 mg

Drug

Primary outcomes

  1. Pharmacokinetics (PK) endpoints in terms of maximum observed concentration (Cmax) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets

    Time frame: Days 1 and Day 8

    Cmax is the maximum observed concentration of a drug after administration

  2. PK endpoints in terms of time of occurrence of maximum observed concentration (tmax) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets

    Time frame: Day 1 and Day 8

    Tmax is the time of occurrence of cmax

  3. PK endpoints in terms of area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint (AUC last) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets

    Time frame: Day 1 and Day 8

    AUC last is the area under the plasma concentration time curve from zero to the last quantifiable sampling timepoint

  4. PK endpoints in terms of area under the plasma concentration time curve from and from zero to infinity (AUC 0-∞) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets

    Time frame: Day 1 and Day 8

    AUC 0-∞ is a meausre of total concentration from time zero to infinity

  5. PK endpoints in terms of apparent terminal half-life (t1/2) for lesinurad/allopurinol 200/300 and 200/200 FDC tablets relative to lesinurad and allopurinol monocomponent tablets

    Time frame: Day 1 and Day 8

    t1/2 is a measure of apparent terminal half-life

Secondary outcomes

  1. Incidence of Adverse Events in terms of changes in laboratory parameters

    Time frame: 6 weeks

  2. Incidence of Adverse Events in terms of electrocardiogram parameters

    Time frame: 6 weeks

  3. Incidence of Adverse Events in terms of vital signs

    Time frame: 6 weeks

  4. Incidence of Adverse Events in terms of physical examination findings

    Time frame: 6 weeks

Sponsors and collaborators

Lead sponsor

Ardea Biosciences, Inc.

Industry

Registry information

Official study title

A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Relative Bioavailability of Lesinurad/Allopurinol Fixed Dose Combination Tablets and Coadministered Lesinurad and Allopurinol Tablets and the Effect of Food on the Pharmacokinetics of Lesinurad/Allopurinol Fixed Dose Combination Tablets in Healthy Adult Male Subjects

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Oct 21, 2015
Registry last updated
Dec 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.